Why TheranosticTrials.org?

The leading global platform for radiopharmaceutical & molecular imaging clinical trials

Global Reach

We are uniquely positioned at the heart of Theranostics.

Increasing Awareness

We're dedicated to increasing awareness about Theranostics and it's potential.

Fostering Engagement

We encourage active participation in the Theranostics community.

Building Connections

We connect physicians, clinics, and patients with Theranostic opportunities.

Comprehensive Resources

Access a complete list of cancer Theranostic Trials and educational materials.

Advancing the Field

We collaborate with key opinion leaders to push Theranostics forward.

Our Ultimate Goal

Provide more hope to cancer patients everywhere!


Navigating Tips

Pick Your Path


Stats

Theranostic Research Report

Source: Oppenheimer & Co. Research

View All


Isotopes

View details about the isotopes used in the trials listed on our site!

Learn more
LUTETIUM-177
Radioisotope: Lu-177
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.7 Days
Decay Mode: BETA, GAMMA
Energy: Eβeta max 497 keV, Gamma 113-208 keV
Range: In Tissue: 0.25-2mm
Decay Daughters: Hf177
Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
SAMARIUM-153
Radioisotope: Sm153
Theranostic Role: Therapeutic
T1/2 (Half-Life): 1.9 Days
Decay Mode: BETA, GAMMA
Energy: Beta: Max 808 keV Gamma: 103 keV (28%)
Range: 0.6 mm
Decay Daughters: Eu153 (Stable)
Status: FDA Approval: QUADRAMET® (1997)
TECHNETIUM-99m
Radioisotope: Tc-99m
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 6 Hours
Decay Mode: GAMMA
Energy: 140 keV (89.1%)
Range: N/A
Decay Daughters: Tc99
Status: FDA Approval: First in 1980’s

DI Badge

Distinguished Investigator

A Distinguished Investigator of Theranostics is a level of distinction conferred upon an individual physician who has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.

Michael J. Morris, MD, PhD

Dr. Morris is a prostate cancer specialist, clinical investigator, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan Kettering Cancer Center, where is also was Chief Fellow. Over the past several decades, Dr. Morris has had a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on tumor and bone-directed radiopharmaceuticals for prostate cancer, both as single agents and as combinatorial regimens. He was a member of the leadership team that developed Lu-177 PSMA-617, which is now FDA approved for men with advanced prostate cancer. He now leads research programs to develop new prostate-specific targets bearing new payloads using novel targeting agents. He has a research interest in developing novel imaging technologies for metastatic prostate cancer and in credentialing imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and prostate-specific imaging technologies such as PSMA-directed PET imaging. In addition, he is the Medical Director of the Prostate Cancer Clinical Trials Consortium. He has long had an interest in novel methods of implementing prostate cancer clinical trials, and utilizing digital methods to reduce barriers to expertise, clinical care, and investigational studies.

Read More
See All Investigators

RLT Components

RADIOLIGAND THERAPY (RLT) is a highly effective approach to very accurately locating cancer cells and effectively killing those same cells by delivery various radioisotopes to a specific target that is located on a type of cancer. Some of the Radioisotopes are diagnostic for locating cancers & some therapeutic to treat the cancers.

There are several Components to a RLT that are simply demonstrated in the truck diagram including:

  1. Cancer Targets
  2. Ligand (demonstrated as the Truck GPS set to find a specific Target)
  3. Diagnostic Radioisotopes (demonstrated as light bulbs that light the cancer Targets on a PET scan)
  4. Therapeutic Radioisotopes (demonstrated as bombs that kill cancer cells that express the target with either Alpha or Beta radiation)
  5. Linker (demonstrated as the hitch keeping the Radioisotope attached to the Ligand)
  6. Chelator (demonstrated as the Trailers which keeps the Radioisotope on Target).

To learn more about the specific components being studied today on clinical trials around the world check out the RLT COMPONENTSTab.

View RLT Components

Education


banana

Sponsors

blueearthdiagnosticsltdadvancedacceleratorapplicationsbayertelixpharmaceuticalsfusionpharmaceuticalsincclaritypharmaceuticalscuriumpointbiopharmaratiotherapeuticsincartbionorthstarnucleusradiopharmaradiopharmtheranosticsinvenraconvergenttherapeuticsterrapowerisotopesnusanorlsradiopharmacies

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468